Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria (COMPOSER)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03157635 |
Recruitment Status :
Active, not recruiting
First Posted : May 17, 2017
Last Update Posted : February 28, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Paroxysmal Hemoglobinuria, Nocturnal | Drug: Crovalimab Drug: Placebo | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 59 participants |
Allocation: | Randomized |
Intervention Model: | Sequential Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | An Adaptive Phase I/II Study to Assess Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Crovalimab in Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Actual Study Start Date : | November 14, 2016 |
Estimated Primary Completion Date : | March 31, 2031 |
Estimated Study Completion Date : | June 10, 2031 |
Arm | Intervention/treatment |
---|---|
Experimental: Part 1 (Healthy Volunteers): Crovalimab
Healthy participants will receive a single dose of crovalimab in each dose-escalation cohort of Part 1. Crovalimab will be administered at a starting dose of 75 milligrams (mg) intravenous (IV) infusion. Doses are planned to be escalated up to Cohort 5.
|
Drug: Crovalimab
Crovalimab will be administered as per schedule described in individual arm. |
Placebo Comparator: Part 1 (Healthy Volunteers): Placebo
Healthy participants will receive a single dose of crovalimab matching placebo in each dose-escalation cohort of Part 1.
|
Drug: Placebo
Placebo will be administered as per schedule described in Part 1 placebo arm. |
Experimental: Part 2 (PNH Participants): Crovalimab
PNH participants will receive 3 single ascending doses (375 mg IV, 500 mg IV, 1000 mg IV of crovalimab) on Days 1, 8, and 22 followed by weekly crovalimab administrations up to a maximum of 5 months. Weekly crovalimab administrations will start no earlier than Day 36. The starting dose of Part 2 is based on data from Part 1 of the study.
|
Drug: Crovalimab
Crovalimab will be administered as per schedule described in individual arm. |
Experimental: Part 3 (PNH Participants): Crovalimab QW
Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 170 mg weekly (QW) starting on Day 8 for a maximum treatment duration of 5 months.
|
Drug: Crovalimab
Crovalimab will be administered as per schedule described in individual arm. |
Experimental: Part 3 (PNH Participants): Crovalimab Q2W
Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 340 mg every 2 weeks (Q2W) for a maximum treatment duration of 5 months.
|
Drug: Crovalimab
Crovalimab will be administered as per schedule described in individual arm. |
Experimental: Part 3 (PNH Participants): Crovalimab Q4W
Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 680 mg every 4 weeks (Q4W) starting on Day 8 for a maximum treatment duration of 5 months.
|
Drug: Crovalimab
Crovalimab will be administered as per schedule described in individual arm. |
Experimental: Part 4 (eculizumab pretreated PNH Participants): Crovalimab
PNH Participants pretreated with eculizumab will receive crovalimab: Participants >/= 100 kilograms (kg): loading dose of 1500 mg IV on Day 1; Participants < 100 kg: loading dose of 1000 mg IV on Day 1. In all Participants, the remainder of the loading series schedule will be 340 mg subcutaneous (SC) on Days 2, 8, 15, and 22. For Participants >/= 100 kg, maintenance dosing will be 1020 mg SC on week 5 and then Q4W thereafter. Patients < 100 kg will receive a maintenance dose of 680 mg SC on the same schedule. |
Drug: Crovalimab
Crovalimab will be administered as per schedule described in individual arm. |
Experimental: Part 4 (treatment naïve PNH Participants): Crovalimab
Treatment naïve PNH Participants will receive: Participants >/= 100 kg: loading dose of 1500 mg IV on day 1; Participants < 100 kg: loading dose of 1000 mg IV on day 1. In all Participants, the remainder of the loading series schedule will be 340 mg SC on Days 2, 8, 15, and 22. For Participants >/= 100 kg, maintenance dosing will be 1020 mg SC on week 5 and then Q4W thereafter. Patients < 100 kg will receive a maintenance dose of 680 mg SC on the same schedule. |
Drug: Crovalimab
Crovalimab will be administered as per schedule described in individual arm. |
Experimental: OLE (PNH Participants): Crovalimab
PNH Participants who participated in Parts 2, 3 and 4 and who derive clinical benefit from crovalimab may enroll into OLE. Participants will either receive 680 mg SC Q4W (body weight >/= 40 kg to < 100 kg) or 1020 mg SC Q4W (body weight >/= 100 kg) for up to a maximum treatment duration of ten years from entry into OLE.
|
Drug: Crovalimab
Crovalimab will be administered as per schedule described in individual arm. |
- Part 1: Percentage of Participants With Dose-Limiting Events (DLEs) [ Time Frame: Baseline up to approximately 3 months ]
- Part 1: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline up to approximately 3 months ]
- Part 2: Percentage of Participants With AEs and SAEs [ Time Frame: Baseline up to approximately 8 months ]
- Part 3: Percentage of Participants With AEs and SAEs [ Time Frame: Baseline up to approximately 8 months ]
- Part 4: Percentage of Participants With AEs and SAEs [ Time Frame: Baseline up to approximately 8 months ]
- Part 2: Terminal Complement Activity in Serum as Assessed by Ex Vivo Liposome Immunoassay (LIA) [ Time Frame: Baseline up to Day 224 ]
- Part 3: Terminal Complement Activity as Assessed by Ex Vivo Liposome Lysis in Serum Using the LIA [ Time Frame: Baseline up to Day 224 ]
- Part 4: Terminal Complement Activity in Serum as Assessed by Ex Vivo Liposome Immunoassay (LIA) [ Time Frame: Baseline up to Day 224 ]
- OLE: Percentage of Participants With AEs and SAEs [ Time Frame: OLE: Week 21 up to Week 567 ]
- Part 1: Terminal Complement Activity as Assessed by Ex Vivo Liposome Immunoassay (LIA) [ Time Frame: Part 1: Baseline up to Day 91 (assessed at predose [Hour 0], end of infusion [EOI] [1 Hour], Hours 2, 6, 12 on Day 1; Days 2, 3, 4, 5, 7, 14, 21, 28, 35, 42, 56, 91) ]
- Part 2: Serum Lactate Dehydrogenase (LDH) Levels [ Time Frame: Predose (Hour 0), Hours 10-12 on Days 1, 8; Days 2, 5, 9, 15, 22, 29, 36, 43, 50, 64, 78, 92, 106, 120, 134, 224 ]
- Part 3: Serum LDH Levels [ Time Frame: Part 3: Predose (Hour 0), Hours 10-12 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 36, 64, 78, 92, 106, 134; Day 224 ]
- Part 4: Serum LDH Levels [ Time Frame: Part 4: Predose (Hour 0), Hour 6 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 43, 57, 85, 113, 134; Day 224 ]
- Part 1: Total Complement Component 5 (C5) Concentration [ Time Frame: Part 1: Predose (Hour 0), EOI (1 Hour), Hours 2, 6, 12 on Day 1; Days 2, 3, 4, 5, 7, 14, 21, 28, 35, 42, 56, 91 ]
- Part 2: Total C5 Concentration [ Time Frame: Part 2: Predose (Hour 0), EOI (1 Hour), Hours 2, 6, 10-12 on Day 1; Days 2, 5, 9, 15, 29, 224; predose [Hour 0], EOI [1 Hour], Hours 10-12 on Days 8, 22; predose [Hour 0] on Days 36, 43, 50, 64, 78, 92, 106, 120, 134 ]
- Part 3: Total C5 Concentration [ Time Frame: Part 3: Predose (Hour 0), EOI (1 Hour), Hours 2 and 6 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 36, 43, 50, 57, 64, 78, 92, 106; Day 224 ]
- Part 4: Total C5 Concentration [ Time Frame: Part 4: Predose (Hour 0), EOI (1 Hour), Hours 2, 6 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 57, 85, 113; Days 43, 134, 224 ]
- Part 1: Free C5 Concentration [ Time Frame: Part 1: Predose (Hour 0), EOI (1 Hour), Hours 2, 6, 12 on Day 1; Days 2, 3, 4, 5, 7, 14, 21, 28, 35, 42, 56, 91 ]
- Part 2: Free C5 Concentration [ Time Frame: Part 2: Predose (Hour 0), EOI (1 Hour), Hours 2, 6, 10-12 on Day 1; Days 2, 5, 9, 15, 29, 224; predose [Hour 0], EOI [1 Hour], Hours 10-12 on Days 8, 22; predose [Hour 0] on Day 36, 43, 50, 64, 78, 92, 106, 120, 134 ]
- Part 3: Free C5 Concentration [ Time Frame: Part 3: Predose (Hour 0), EOI (1 Hour), Hours 2, 6 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 36, 43, 50, 57, 64, 78, 92, 106; Day 224 ]
- Part 4: Free C5 Concentration [ Time Frame: Part 4: Predose (Hour 0), EOI (1 Hour), Hours 2, 6 on Day 1; predose (Hour 0), on Days 2, 8, 15, 22, 29, 57, 85, 113; Days 43, 134, 224 ]
- Part 2: Change From Baseline in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Score at Day 64 [ Time Frame: Baseline, Day 64 ]
- Part 3: Change From Baseline in Fatigue as Measured by FACIT-Fatigue Scale Score at Day 8, 22, 50, 78, 106, and 134 [ Time Frame: Baseline, Day 8, 22, 50, 78, 106, 134 ]
- Part 4: Change From Baseline in Fatigue as Measured by FACIT-Fatigue Scale Score at Day 8, 22, 57, 85, 113 and 134 [ Time Frame: Baseline, Day 8, 22, 57, 85, 113, 134 ]
- Part 2: Change From Baseline in Health-Related Quality of Life (HRQoL) as Measured by European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Score at Day 64 [ Time Frame: Baseline, Day 64 ]
- Part 3: Change From Baseline in HRQoL as Measured by EORTC QLQ-C30 Score at Day 78 and 134 [ Time Frame: Baseline, Day 78, 134 ]
- Part 4: Change From Baseline in HRQoL as Measured by EORTC QLQC30 Score at Day 85 and 134 [ Time Frame: Baseline, Day 85, 134 ]
- Part 2: Participant Treatment Satisfaction as Measured by Treatment Satisfaction Questionnaire for Medication (TSQM) Score at Day 8, 22, 36, 50 and 64 [ Time Frame: Baseline, Day 8, 22, 36, 50, 64 ]
- Part 3: Participant Treatment Satisfaction as Measured by TSQM Score at Day 8 and 50 [ Time Frame: Baseline, Day 8, 50 ]
- Part 4: Participant Treatment Satisfaction as Measured by TSQM Score at Day 8 and 57 [ Time Frame: Baseline, Day 8, 57 ]
- Part 2: Number of Packed Red Blood Cell (RBC) Units Transfused per Participant [ Time Frame: Baseline up to Day 224 ]
- Part 3: Number of Packed RBCs Units Transfused per Participant [ Time Frame: Baseline up to Day 224 ]
- Part 4: Number of Packed RBCs Units Transfused per Participant [ Time Frame: Baseline up to Day 224 ]
- Part 2: Percentage of Participants With Packed RBC Units Transfused [ Time Frame: Baseline up to Day 224 ]
- Part 3: Percentage of Participants With Packed RBC Units Transfused [ Time Frame: Baseline up to Day 224 ]
- Part 4: Percentage of Participants With Packed RBC Units Transfused [ Time Frame: Baseline up to Day 224 ]
- Part 1: Percentage of Participants With Anti-Drug Antibodies (ADAs) to Crovalimab [ Time Frame: Part 1: Day 1 up to Day 91 (assessed at predose [Hour 0] on Day 1; on Days 14, 28, 56, 84, and 91) ]
- Part 2: Percentage of Participants With ADAs to Crovalimab [ Time Frame: Part 2: Day 1 up to Day 224 (assessed at predose [Hour 0] on Days 1, 8, 50, 106, 134); Days 29, 224 ]
- Part 3: Percentage of Participants With ADAs to Crovalimab [ Time Frame: Part 3: Day 1 up to Day 106 assessed at predose [Hour 0] on Days 1, 8, 29, 64, and 106; Day 224 ]
- Part 4: Percentage of Participants With ADAs to Crovalimab [ Time Frame: Day 1 up to Day 224 (assessed at predose [Hour 0] on Days 1, 8, 29, 113); Days 134, 224 ]
- OLE: Total C5 Concentration [ Time Frame: OLE: Predose (Hour 0) on Week 36 up to Week 521 ]
- OLE: Serum LDH Levels [ Time Frame: OLE: Predose (Hour 0) on Week 28 up to Week 521 ]
- OLE: Terminal Complement Activity in Serum as Assessed by Ex Vivo Liposome Immunoassay (LIA) [ Time Frame: OLE: Week 36 up to Week 521 ]
- Part 2: Percentage of Participants With LDH Below Upper Limit of Normal (ULN) [ Time Frame: Baseline up to Day 224 ]
- Part 3: Percentage of Participants With LDH Below ULN [ Time Frame: Baseline up to Day 224 ]
- Part 4: Percentage of Participants With LDH Below ULN [ Time Frame: Baseline up to Day 224 ]
- Part 2: Percentage of Participants With Complement Suppression [ Time Frame: Baseline up to Day 134 ]
- Part 3: Percentage of Participants With Complement Suppression [ Time Frame: Baseline up to Day 134 ]
- Part 4: Percentage of Participants With Complement Suppression [ Time Frame: Baseline up to Day 134 ]
- Part 2: Monthly Rate of pRBC Transfusions per Participant [ Time Frame: Baseline up to 10 years ]
- Part 3: Monthly Rate of pRBC Transfusions per Participant [ Time Frame: Baseline up to 10 years ]
- Part 4: Monthly Rate of pRBC Transfusions per Participant [ Time Frame: Baseline up to 10 years ]
- Part 2: Proportion of Transfusion-Free Participants [ Time Frame: Baseline up to 10 years ]
- Part 3: Proportion of Transfusion-Free Participants [ Time Frame: Baseline up to 10 years ]
- Part 4: Proportion of Transfusion-Free Participants [ Time Frame: Baseline up to 10 years ]
- Part 2: Annual Rate of Transfusion Avoidance per Participant [ Time Frame: Baseline up to 10 years ]
- Part 3: Annual Rate of Transfusion Avoidance per Participant [ Time Frame: Baseline up to 10 years ]
- Part 4: Annual Rate of Transfusion Avoidance per Participant [ Time Frame: Baseline up to 10 years ]
- Part 2: Annual Rate of Breakthrough Hemolysis (BTH) [ Time Frame: Baseline up to 10 years ]
- Part 3: Annual Rate of Breakthrough Hemolysis (BTH) [ Time Frame: Baseline up to 10 years ]
- Part 4: Annual Rate of Breakthrough Hemolysis (BTH) [ Time Frame: Baseline up to 10 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Part 1 (HVs only):
- Healthy male volunteers, aged between 21 and 55 years inclusive
- Participants with a negative hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C antibody, and human immunodeficiency virus (HIV) test result
- Participants who have been vaccinated against hepatitis B
- No evidence of Neisseria meningococci in nasopharyngeal swab
- Neisseria meningitidis vaccination against serogroups B and A, C, W, and Y
- Non-smokers, or former smokers, who have not smoked for at least 60 days prior to screening
Parts 2, 3 and 4 (PNH participants only):
- Male or female participants with PNH between 18 and 75 years of age
- Neisseria meningitidis vaccination in accordance with most current local guidelines or standard of care (SOC) for participants at increased risk for meningococcal disease (Part 2 and 4)
- Participant has been vaccinated with Neisseria meningitidis vaccine(s) in accordance with most current local guidelines or SOC for participants at increased risk for meningococcal disease or is being revaccinated if applicable (Part 3 and 4)
- Antibiotic prophylaxis for meningococcal infection must be initiated prior to initiation of crovalimab therapy if the time period between initial Neisseria meningitidis vaccination and first dose of crovalimab is less than 2 weeks (Part 2 and 4)
- Antibiotic prophylaxis of meningococcal infection may be initiated prior to initiation of crovalimab therapy based on local guidelines or SOC for participants at increased risk for meningococcal disease e.g., splenectomized patients (Parts 2 and 4)
- Stable dose for greater than or equal to (>/=) 28 days prior to screening of other therapies (immunosuppressant therapy, corticosteroids, iron supplements)
Part 2 and 4 (currently untreated PNH participants who are candidates for treatment with complement inhibitors only):
- PNH participants who have not been treated with any complement inhibitor or if previously treated stopped treatment due to lack of efficacy based on a single missense C5 heterozygous mutation
- Serum LDH levels at least 1.5-fold above the ULN at screening
- Hepatitis B participants can be enrolled if their liver function test values are less than 2 x ULN and there is no liver function impairment
Part 3 and 4 (PNH participants currently treated with eculizumab only):
- PNH participants who have been treated continuously with eculizumab for at least 3 months preceding enrollment in the trial
- Participants receive regular infusions of eculizumab
- Subjects with a negative hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C antibody, and HIV test result
OLE only - PNH participants:
- PNH participants who have completed Parts 2, 3 and 4 respectively
- PNH participants who derived, in the investigator's opinion, benefit from treatment with crovalimab
- Vaccination currency for Neisseria meningitidis serotypes A, C, W, Y and B should be maintained throughout the OLE
All Parts:
- Female participants should use proper means of contraception
Exclusion Criteria:
Part 1 (HVs only):
- Any clinically relevant history or the presence of moderate to severe respiratory, renal, hepatic, gastrointestinal, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, or connective tissue disease
- Any major illness within 1 month before the screening
- Prior splenectomy
- History of clinically significant hypersensitivity (example: drugs, excipients) or allergic reactions
- History or presence of clinically significant electrocardiogram (ECG) abnormalities or cardiovascular disease
- Any contra-indication for receiving Neisseria meningitides vaccination and antibiotic prophylaxis therapy as required in the study
- Congenital or acquired complement deficiency
- Carriers of Neisseria meningitides based on cultures from nasopharyngeal swabs
- Known active viral, bacterial or fungal infection including herpes, herpes zoster or cold sores, during the last 14 days prior to first study drug administration
- Signs of parasitic infection (example: eosinophilia, diarrhea)
- History of significant recurrent infections in the opinion of the investigator
Parts 2, 3 and 4 - PNH participants only:
- Evidence of moderate to severe concurrent renal, liver, cardiac, pulmonary or gastrointestinal disease not related to PNH as determined by the investigator
- History of an illness that, in the opinion of the study investigator, might confound the results of the study or that poses an additional risk to the participant by his or her participation in the study
- History of bone marrow transplantation
- Treatment with azathioprine or erythrocyte-stimulating agents within 14 days prior to first study drug administration
- Splenectomy <1 year before start of crovalimab.
Part 3 and 4 - PNH patients only:
- Any evidence of sero-positive auto-immune connective tissue diseases (such as systemic lupus erythematosus, or rheumatoid arthritis)
- Any evidence of active inflammatory conditions (including inflammatory bowel disease, or cryoglobulinemia)
All Parts:
- Under active therapy with intravenous immunoglobulin (IVIG)
- Mentally incapacitated or history of a clinically significant psychiatric disorder over the previous 5 years
- Known or suspected hereditary complement deficiency
- History of meningococcal meningitis
- History of allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies or known hypersensitivity to any constituent of the product
- Any major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 28 days prior to screening or oral antibiotics within 2 weeks prior to screening and up to first study drug administration
- History of or currently active primary or secondary immunodeficiency, including known history of human immunodeficiency virus (HIV) infection
- Evidence of chronic active hepatitis C infection
- Evidence of malignant disease including myelodysplastic syndrome, or malignancies diagnosed within the previous 5 years
- Pregnant or breastfeeding, or intending to become pregnant during the study, including the OLE period, within 46 weeks (approximately 10.5 months) after the final dose of crovalimab
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03157635
Study Director: | Clinical Trials | Hoffmann-La Roche |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT03157635 |
Other Study ID Numbers: |
BP39144 2016-002128-10 ( EudraCT Number ) 2023-506287-14-00 ( Other Identifier: EU Trial Number ) |
First Posted: | May 17, 2017 Key Record Dates |
Last Update Posted: | February 28, 2024 |
Last Verified: | February 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/innovation/process/clinical -trials/data-sharing/) |
Hemoglobinuria Hemoglobinuria, Paroxysmal Proteinuria Urination Disorders Urologic Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases |
Male Urogenital Diseases Urological Manifestations Anemia, Hemolytic Anemia Hematologic Diseases Myelodysplastic Syndromes Bone Marrow Diseases |